Skip to main content
. 2016 Dec 11;7(52):86039–86050. doi: 10.18632/oncotarget.13325

Figure 5. IFITM1 mediates EMT signature through Caveolin-1.

Figure 5

Control (shLacZ) or IFITM1-depleted (shIFITM1) SW620 cells were treated with either control siRNA or siCAV1 for 2 days and RT-qPCR was conducted to measure the mRNA expression of IFITM1 (A) Caveolin-1 (B) and EMT signature (D) (*p < 0.05, **p < 0.001). (C) Control (shLacZ) or IFITM1-depleted (shIFITM1) SW620 cells were treated with either control siRNA or siCAV1 and then analyzed for migration ability (C). Data shown are from three experiments (**p < 0.001).